Has Peter Attia publicly confirmed using TRT and rapamycin?

Yes. Attia has confirmed personal use of both testosterone replacement therapy and weekly low-dose rapamycin in his book *Outlive*, on his podcast *The Drive*, and in multiple public interviews. These are documented first-person disclosures, not speculation.

What happens to testosterone levels after stopping TRT?

Endogenous testosterone production is suppressed during TRT. After stopping, the HPG axis must recover, which can take 6 to 12 months. Some men, particularly older patients or those on long-term therapy, may not fully recover baseline levels. Recovery protocols using clomiphene or hCG exist but have variable results.

Is rapamycin FDA-approved for longevity?

No. Rapamycin is FDA-approved for preventing organ transplant rejection and treating lymphangioleiomyomatosis. All use for longevity or healthspan extension is off-label. No randomized controlled trial has tested rapamycin for this purpose in healthy humans over multi-year periods.

Does stopping rapamycin cause withdrawal or rebound?

No hormonal rebound occurs. Rapamycin does not suppress an endogenous production axis. mTOR signaling returns to baseline within roughly two weeks of the last dose. The concern is not rebound but potential loss of accumulated benefit, based on animal data showing lifespan effects require ongoing treatment.

What monitoring does long-term rapamycin use require?

Regular monitoring should include fasting lipids (LDL and triglycerides can rise), fasting glucose and insulin sensitivity markers, complete blood count, liver function, and clinical assessment of immune status. Mouth ulcers and impaired wound healing are known side effects even at low doses.

Peter Attia, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Celebrity: Peter Attia, MD
Drug family: Longevity (TRT + Rapamycin)
Status: Confirmed personal use of both, disclosed in interviews, podcasts, and his 2023 book Outlive
This page's focus: Clinical evidence on discontinuation, rebound effects, and long-term maintenance for TRT and rapamycin
HealthRX Medical Team position: Both drugs carry real tradeoffs on cessation; neither should be started without a plan for monitoring and, potentially, stopping

What Peter Attia Has Publicly Confirmed

Peter Attia is a Stanford- and Hopkins-trained physician who has built a medical practice and media presence around the concept of "Medicine 3.0," a proactive, biomarker-driven approach to extending healthspan. In his 2023 book Outlive: The Science and Art of Longevity, Attia confirmed that he personally uses testosterone replacement therapy. He has discussed his TRT protocol across multiple episodes of his podcast, The Drive, including specific references to monitoring hematocrit, PSA, and estradiol levels.

Attia has also publicly confirmed weekly off-label rapamycin use on his podcast and in interviews, describing a protocol of approximately 5 to 6 mg taken once per week. He has framed this as a deliberate experiment, citing the drug's mTOR-inhibition profile and the preclinical evidence on lifespan extension in animal models. He has been explicit that this is off-label, that clinical trial data in healthy humans remains limited, and that he monitors his bloodwork closely.

These disclosures are not speculation. Attia has spoken about both protocols on camera, in print, and in clinical detail. What remains private is the exact dosing, timing, and any modifications he may have made since his last public statements.

TRT: What the Evidence Says About Stopping

Testosterone replacement therapy suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) output, which in turn lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. The result: endogenous testosterone production drops, and spermatogenesis can slow or stop entirely (Endocrine Society Clinical Practice Guidelines, 2018).

When TRT is discontinued, the HPG axis must recover. In younger men, this recovery can take weeks to months. In older men or those on TRT for years, recovery may be incomplete. A 2019 study in the Journal of Clinical Endocrinology & Metabolism found that while most men regained baseline testosterone levels within 6 to 12 months of stopping, a subset showed persistently low levels at 18 months (Kohn et al., 2019).

During the recovery window, patients commonly report:

Fatigue and reduced energy
Decreased libido
Mood changes, including irritability and depressive symptoms
Loss of lean mass and increased body fat
Reduced exercise capacity

These are not withdrawal symptoms in the pharmacological sense. They are the symptoms of hypogonadism returning before the body's own production catches up. For men whose baseline testosterone was already low before starting TRT, discontinuation can feel worse than the original condition, because the body has adapted to a higher set point.

The HealthRX Medical Team take: Attia has been candid that TRT is not a casual decision. The clinical reality supports this. Any man considering TRT should discuss an exit strategy with his physician before starting. Post-cycle recovery protocols using clomiphene citrate or human chorionic gonadotropin (hCG) have shown variable success in restarting endogenous production (McCullough et al., 2020), but outcomes depend heavily on age, duration of use, and individual physiology.

TRT: Long-Term Monitoring Requirements

For those who stay on TRT, the monitoring burden is nontrivial. The Endocrine Society recommends:

Hematocrit every 6 to 12 months (TRT raises red blood cell counts; polycythemia is the most common safety signal)
PSA monitoring at baseline, 3 to 6 months, then annually
Lipid panels, as TRT can lower HDL cholesterol (Fernández-Balsells et al., 2010)
Liver function tests
Bone density screening as clinically indicated
Cardiovascular risk assessment, particularly in light of the TRAVERSE trial (2023), which found no increased rate of major adverse cardiovascular events in hypogonadal men aged 45, 80 but did observe a higher incidence of pulmonary embolism, atrial fibrillation, and acute kidney injury in the treatment group

Attia has publicly described running comprehensive bloodwork multiple times per year. This is consistent with best practice but also reflects the reality that long-term TRT is an active medical relationship, not a set-and-forget prescription.

Rapamycin: The More Uncertain Equation

Rapamycin (sirolimus) is FDA-approved as an immunosuppressant for organ transplant recipients and for the treatment of lymphangioleiomyomatosis. Its use for longevity is entirely off-label, based primarily on animal data. In mice, rapamycin has extended median lifespan by 9 to 14% even when initiated late in life (Harrison et al., 2009). The proposed mechanism is inhibition of mTORC1, a nutrient-sensing pathway that regulates cell growth, autophagy, and protein synthesis.

Attia's confirmed protocol of weekly low-dose rapamycin is designed to preferentially inhibit mTORC1 while minimizing suppression of mTORC2, which is associated with the immunosuppressive and metabolic side effects seen at transplant-level dosing. This distinction matters clinically: mTORC1 inhibition promotes autophagy and may reduce cellular senescence, while chronic mTORC2 suppression impairs glucose metabolism and immune function (Lamming et al., 2012).

Rapamycin: What Happens When You Stop

Unlike TRT, rapamycin does not suppress an endogenous production axis. There is no hormonal rebound on cessation. The drug has a half-life of roughly 62 hours, and after discontinuation, mTOR signaling returns to baseline within approximately two weeks.

The more relevant question is whether the benefits persist. In animal models, the lifespan effects of rapamycin appear to require ongoing exposure. Mice taken off rapamycin after a period of treatment did not retain the full survival benefit compared to those maintained on it continuously (Bitto et al., 2016). This suggests that rapamycin's effects on aging are at least partly maintenance-dependent rather than permanently restorative.

For human users, discontinuation is straightforward from a safety perspective but may erase any accumulated benefit. The honest clinical answer is that no one knows for certain, because no randomized controlled trial has tested rapamycin for longevity in healthy humans over multi-year horizons.

Rapamycin: Long-Term Side Effects Worth Tracking

Even at low weekly doses, rapamycin carries a monitoring profile that the HealthRX Medical Team considers essential:

Lipids: Rapamycin can raise LDL cholesterol and triglycerides. This effect is dose-dependent but has been observed even at sub-immunosuppressive doses (Morrisett et al., 2002).
Glucose metabolism: Chronic mTOR inhibition can impair insulin sensitivity and raise fasting glucose. Attia has publicly noted monitoring his oral glucose tolerance tests (FDA label for sirolimus).
Immune function: While weekly dosing aims to avoid frank immunosuppression, the line between "immune modulation" and "immune suppression" is not well defined at these doses in healthy individuals. A 2014 trial in elderly volunteers showed that a related drug (everolimus) at low doses actually improved vaccine response (Mannick et al., 2014), but this was a short-term study.
Wound healing: Rapamycin impairs wound healing at higher doses. Users considering elective surgery should discuss a washout period with their physician.
Mouth ulcers: Aphthous stomatitis is the most common patient-reported side effect, even at low doses.

The Bigger Clinical Picture

The HealthRX Medical Team take: Attia's transparency is unusual and, in the HealthRX Medical Team's view, valuable. He models a behavior that most longevity-medicine patients should adopt: treat every pharmacological intervention as a monitored experiment with defined endpoints, regular bloodwork, and an explicit willingness to stop if the risk profile changes.

The two drugs he has confirmed sit at opposite ends of the evidence spectrum. TRT for diagnosed hypogonadism has decades of clinical trial data, established monitoring guidelines, and well-characterized discontinuation effects. Rapamycin for longevity has strong preclinical signals, a plausible mechanism, and almost no controlled human evidence for this specific use case.

What both share is that stopping is not free. TRT cessation triggers a hormonal recovery period that can take months and may not return the patient to baseline. Rapamycin cessation is physiologically simpler but may forfeit whatever benefit was accruing. Neither drug, once started, is a casual commitment.

For patients considering either protocol, the HealthRX Medical Team recommends establishing three things before the first dose: a monitoring schedule, a defined threshold for discontinuation, and a relationship with a physician who will actually review the data.

Frequently asked questions

›